市場調查報告書
商品編碼
1086961

顯影劑的全球市場預測(2022年∼2027年)

Global Contrast Materials Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球顯影劑的市場規模,在預測期間內預計以3.67%的年複合成長率成長,從2020年的40億3,800萬美元,2027年達到51億9,600萬美元。

世界人口和高齡人口的增加慢性疾病的擴大,及核醫學的普及,預計促進全球顯影劑市場成長。

本報告提供全球顯影劑市場調查,市場概要,市場促進因素和阻礙因素,各產品類型、給藥途徑、醫療治療、適應症、地區的分析,競爭情形,企業簡介等資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 替代品的威脅
    • 新加入業者的威脅
    • 產業的競爭情形
  • 產業的價值鏈分析

第5章 全球顯影劑市場:各產品類型

  • 簡介
  • 碘為基礎
  • 硫酸鋇
  • 生理食鹽水、氣體(微氣泡)
  • 其他

第6章 全球顯影劑市場:各給藥途徑

  • 簡介
  • 口服
  • 直腸
  • 血管

第7章 全球顯影劑市場:各醫療治療

  • X光/CT
  • MRI
  • 超音波

第8章 全球顯影劑市場:各適應症

  • 循環系統疾病
  • 癌症
  • 腸胃障礙
  • 神經疾病
  • 其他的適應症

第9章 全球顯影劑市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 其他

第10章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場的有利性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第11章 企業簡介

  • Bayer AG
  • General Electric Company
  • Guerbet
  • Bracco Diagnostic, Inc.
  • Nano Therapeutics Pvt. Ltd.
  • Lantheus Medical Imaging, Inc.
  • iMax
  • Trivitron Healthcare
  • Spago Nanomedical AB
  • Jodas Expoim
目錄
Product Code: KSI061612143

The global contrast materials market is projected to grow at a CAGR of 3.67% during the forecast period to reach US$5.196 billion by 2027, from US$4.038 billion in 2020. To examine interior bodily organs or soft tissues, contrast materials, also known as contrast agents or contrast media, are used. These help radiologists distinguish between normal and pathological conditions. Contrast substances can be given orally, rectally, or through blood vessels (veins or arteries ). Contrast agents aid in the enhanced visibility of biological structures as well as the capture of difficult-to-image anatomical areas. They help to eliminate radiologist perception errors, which can affect how the true structure of the underlying anatomy is interpreted. Low-osmolality contrast agents, which are safer and recommended for paediatric patients, have evolved through time from high-osmolar contrast media (HOCM), which have limited value and significant side effects.

The prevalence of chronic diseases among the world's rising population, the ageing population, and of nuclear medicine are expected to fuel the growth of the global contrast materials market.

As the global frequency of chronic diseases rises, the demand for diagnostic imaging procedures also increases and, as a result, contrast materials. Chronic disease costs $3.5 trillion in annual health care costs, according to the National Center for Chronic Disease Prevention and Health Promotion. The Arthritis Foundation estimates that 55 million people have been diagnosed with arthritis. Moreover, about 305,000 newborns and toddlers suffer from arthritis or rheumatic disorders. Osteoarthritis affects approximately 55 million people worldwide. According to the International Osteoporosis Foundation, 220 million women worldwide were affected by osteoporosis in 2019.

Due to the growing demand for imaging operations, contrast media manufacturers have invested much in R&D in order to bring new products to market and gain approval for new indications. Bracco, for example, received FDA approval in 2021 for Lumason, an ultrasound contrast agent, in a 20-vial pack design. According to a report to the Center for Medicare and Medicaid Services (CMS) by the Medicare Payment Advisory Commission (MedPAC), the increase in the volume of imaging services per Medicare beneficiary is the largest among all other services offered by physicians. Imaging techniques like computed tomography (CT), magnetic resonance imaging (MRI), and X-rays have become a standard aspect of most disease diagnoses. Diagnostic imaging modalities are becoming more widely employed as a result of developments in the underlying technology, which includes everything from equipment to administration. Novel solutions, such as syringeless injectors and innovative packaging, aid in the delivery of the correct dose of contrast agents while also reducing waste. The Gadavist Imaging Bulk Package with transfer spike, for example, was authorised by the US FDA in August 2020, allowing for weight-based and multi-patient dosing as well as addressing hospital vial waste issues. It is expected that the approval of such innovative packaging will raise demand for the chemical agent.

Contrast materials are usually regarded as safe for use in MRI and CT scans, among other diagnostic techniques. However, some of the adverse effects and allergic responses associated with its use may limit market expansion. Their side effects range from mild to severe; severe reactions are extremely rare, as are major allergic reactions to contrast materials. In addition, handling complex and sophisticated diagnostic imaging technologies necessitates a high level of technical ability and expertise. According to the US Bureau of Labor Statistics, the employment of radiology technologists is expected to expand by roughly 7% between 2019 and 2029. Despite this, a scarcity of specialists and radiologists will pose a hindrance to industry expansion.

By region, North America is expected to drive the growth of the global contrast materials market during the forecast period.

The existence of prominent players in the region, the high prevalence of chronic illnesses, the growing elderly population, and the increasing use of minimally invasive procedures all contribute to the region's significant share of the market. In the United States, the first gadolinium-based contrast agent was approved. Four agents have been certified in the United States in the last decade, indicating a clear trend in the industry to identify more efficient, accurate, and safe agents. In the future, sales of contrast materials are likely to rise in the United States. Contrast material sales for ultrasound may have a significant growth rate among the various imaging modalities. In the United States, the rise in chronic conditions such as cardiovascular and neurological diseases is the primary driver of market growth.

During the predicted period, Asia Pacific is also expected to increase significantly. This is because the region is home to a number of well-known local and worldwide manufacturers. For example, General Electric Pharmaceuticals (Shanghai) Co., Ltd., is a GE Healthcare subsidiary that manufactures diagnostic pharmaceuticals (CT/MR contrast media) in China and is one of the world's largest contrast material manufacturing facilities. This aspect is expected to continue to drive regional market expansion.

Covid-19 Insights

Due to fewer patient visits to hospitals, the COVID-19 outbreak had a detrimental influence on the contrast materials industry. As a result of the epidemic, healthcare systems have been severely stressed. To prevent the spread of the disease and conserve healthcare resources for COVID-19 patients, healthcare institutes and providers were told to halt performing elective surgical operations and medical evaluations. As a result, the volume of imaging cases in many radiology departments dropped dramatically.

Due to a fall in the volume of optional and non-essential procedures, lower utilisation of routine testing, decreased capital spending by customers, and a slowdown in research activity owing to laboratory closures and decreased clinical testing, the worldwide contrast materials market has been impacted.

Market Segmentation:

  • By Product Type

Iodine-based

Barium-Sulphate

Gadolinium

Saline and Gas

Others

  • By Route of Administration

Oral

Rectal

Blood Vessel

  • By Medical Procedure

X-Ray/CT

MRI

Ultrasound

  • By Indication

Cardiovascular Disease

Oncology

Gastrointestinal Disorders

Neurological Disorders

Other Indications

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL CONTRAST MATERIALS MARKET, BY PRODUCT TYPE 

  • 5.1. Introduction
  • 5.2. Iodine-based
  • 5.3. Barium-Sulphate
  • 5.4. Gadolinium
  • 5.5. Saline and Gas
  • 5.6. Others

6. GLOBAL CONTRAST MATERIALS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Rectal
  • 6.4. Blood Vessel

7. GLOBAL CONTRAST MATERIALS MARKET, BY MEDICAL PROCEDURE

  • 7.1. X-Ray/CT
  • 7.2. MRI
  • 7.3. Ultrasound

8. GLOBAL CONTRAST MATERIALS MARKET, BY INDICATION

  • 8.1. Cardiovascular Disease
  • 8.2. Oncology
  • 8.3. Gastrointestinal Disorders
  • 8.4. Neurological Disorders
  • 8.5. Other Indications

9. GLOBAL CONTRAST MATERIALS MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. United States
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. Israel
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. South Korea
    • 9.6.4. India
    • 9.6.5. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Emerging Players and Market Lucrativeness
  • 10.3. Mergers, Acquisition, Agreements, and Collaborations
  • 10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

  • 11.1. Bayer AG
  • 11.2. General Electric Company
  • 11.3. Guerbet
  • 11.4. Bracco Diagnostic, Inc.
  • 11.5. Nano Therapeutics Pvt. Ltd.
  • 11.6. Lantheus Medical Imaging, Inc.
  • 11.7. iMax
  • 11.8. Trivitron Healthcare
  • 11.9. Spago Nanomedical AB
  • 11.10. Jodas Expoim